Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME^®

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Elevated low-density lipoprotein (LDL)-cholesterol is a known risk factor for cardiovascular disease.
• Understanding how LDL-cholesterol levels influence treatment efficacy is crucial for personalized medicine.

Purpose of the Study:

• To evaluate the cardiovascular outcomes of empagliflozin in patients with type 2 diabetes across various baseline LDL-cholesterol levels.
• To determine if the benefits of empagliflozin on cardiovascular events are consistent irrespective of initial LDL-cholesterol concentrations.

Main Methods:

• The EMPA-REG OUTCOME trial randomized patients with type 2 diabetes and high cardiovascular risk to receive empagliflozin or placebo.
• Subgroup analyses were performed based on baseline LDL-cholesterol categories (<1.8, 1.8–<2.2, 2.2–<2.6, 2.6–3.0, and >3.0 mmol/L).
• Cox regression models assessed the interaction between treatment and baseline LDL-cholesterol categories for major adverse cardiovascular events (3P-MACE), cardiovascular death, heart failure hospitalizations, and all-cause mortality.

Main Results:

• Empagliflozin demonstrated consistent reductions in cardiovascular outcomes across all analyzed baseline LDL-cholesterol categories (interaction p > 0.05).
• The study included 7020 participants, with 81.0% receiving lipid-lowering therapy, including 77.0% on statins.
• While baseline characteristics varied slightly between LDL-cholesterol groups, empagliflozin's benefits remained uniform.

Conclusions:

• The cardiovascular benefits of empagliflozin are consistent across a wide range of baseline LDL-cholesterol levels in patients with type 2 diabetes.
• Empagliflozin offers reliable cardiovascular protection irrespective of a patient's initial LDL-cholesterol status.